Study for multiple myeloma resistance and relapse changes
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma or your multiple myeloma has come back
- Your diagnosis must match the international criteria doctors use for multiple myeloma
- You must be able and willing to sign consent and allow use of your biological samples (biocollection)
- You must be covered by a social security program or similar healthcare coverage
- You cannot be a minor, and you cannot be under major guardianship/curatorship
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This is a study that collects information from people diagnosed with multiple myeloma. It may help researchers understand the disease and improve future care by using past and ongoing patient data.
This study collects information from multiple myeloma patients who previously took part in a GMMG therapy study. It helps researchers learn more about the disease and treatments over time.
This trial enrolls people with multiple myeloma who are starting (or have recently started) standard drug treatment, so researchers can collect real-world information about patients’ experiences and outcomes. It may help by improving future care planning and study designs, while adding an extra set of questionnaires to your routine.
This study is for people with newly diagnosed multiple myeloma whose cancer responded to initial treatment but still has tiny traces (minimal residual disease, or MRD). The trial will test if adjusting the next phase of therapy based on MRD levels can improve long-term outcomes.
This study looks at how patients with multiple myeloma are doing over time and what factors might affect their health. The goal is to learn more about the disease and improve care.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.